4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-039810
Chief Business Officer sold 7,500 shares at an average $29.37 ($220,248)
- Chief Business Officer acquired 7,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Beaurang Pierre · Chief Business Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-06-10 | Exercise or conversion : show line 1 in the form | +7,500 | $1.11 | $8,325 | 11,830 | D |
| 2021-06-10 | Sale : show line 2 in the form | −6,000 | $29.15 | $174,881 | 5,830 | D |
| 2021-06-10 | Sale : show line 3 in the form | −1,100 | $30.01 | $33,006 | 4,730 | D |
| 2021-06-10 | Sale : show line 4 in the form | −400 | $30.90 | $12,361 | 4,330 | D |
| Open-market sales · 7,500 sh · avg $29.37 · $220,248 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2021-06-10 | Exercise or conversion : show line 5 in the form Employee Stock Option (right to buy) | −7,500 | $1.11 | 2027-02-01 | 7,500 | 21,562 | D |
Loading xslF345X03/doc4.xml…